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Abstract
Immunotherapy targeting glioblastoma initiating cells (GIC) is considered a promising strat-
egy. However, GIC are prone to evade immune response and there is a need for potent adju-
vants. IFN-βmight enhance the immune response and here we define its net effect on the
innate immunogenicity of GIC. The transcriptomes of GIC treated with IFN-β and controls
were assessed by microarray-based expression profiling for altered expression of immune
regulatory genes. Several genes involved in adaptive and innate immune responses were
regulated by IFN-β. We validated these results using reverse transcription (RT)-PCR and
flow cytometry for corresponding protein levels. The up-regulation of the NK cell inhibitory
molecules HLA-E and MHC class I was balanced by immune stimulating effects including
the up-regulation of nectin-2. In 3 out of 5 GIC lines tested we found a net immune stimulating
effect of IFN-β in cytotoxicity assays using NKL cells as effectors. IFN-β therefore warrants
further investigation as an adjuvant for immunotherapy targeting GIC.
Introduction
Despite multimodal approaches including surgery, radio- and chemotherapy, the efficacy of
glioblastoma treatment remains limited, with an overall survival of about one year [1, 2]. New
therapeutic options are needed to overcome this devastating disease and the use of immuno-
therapy is considered a promising option [3]. Possible strategies comprise immune check point
inhibitors such as ipilimumab or nivolumab as well as active cellular immunotherapy or vacci-
nation. The feasibility and safety of such approaches has been demonstrated in humans, how-
ever, no controlled trial has demonstrated a relevant and robust improvement of survival of
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glioblastoma patients (reviewed in [4–7]). Glioma cells express ligands for activating immune
receptors like natural killer group 2 member D (NKG2D) or DNAX accessory molecule
(DNAM)-1 [8–11], and should therefore be prone to recognition and elimination by the
immune system. The insufficient response to immunotherapies may in part be due to immune
evasive mechanisms in gliomas such as the down-regulation of ligands for NKG2D by trans-
forming growth factor (TGF)-β [8, 10, 11] and certain miRNA species [12] or the expression of
immune inhibitory proteins like HLA-E or—G [13–15].
New adjuvant strategies might help to overcome resistance to immune control in glioma.
Interferons (IFN) have been explored as adjuvants for immunotherapies in cancer entities like
melanoma or renal cell carcinoma in humans [16]. The type I IFN (IFN-α and IFN-β) and type
II IFN, such as IFN-γ, are the best characterized and clinically most relevant IFN. Stimulation
with IFN leads to an up-regulation ofmajor histocompatibility complex (MHC) -I and -II gene
expression as well as antigen presentation in dendritic cells (DC) [17–19], and glioma cells [11,
13, 15, 18], enhancing antigen-presenting capabilities. Moreover, recent reports in mice and
humans describe an immune-independent direct anti-tumor activity of IFN-β [20]. Glioma
cells might be sensitized to the alkylating agent temozolomide (TMZ) [21, 22], and combined
therapy of IFN-β and TMZ resulted in a favorable outcome in patients with tumors with O6-
methylguanine DNAmethyltransferase (MGMT) promotor methylation [23]. Modulation of
tumor vasculature [24], down-regulation of MGMT expression [21, 23] and induction of apo-
ptosis by IFN-β independently of MGMT-mediated resistance to temozolomide [25–27] have
been discussed as mechanisms of this anti-glioma effect. Based on these multi-directional activ-
ities, IFN-β warrants further evaluation as an adjuvant for anti-glioma immunotherapies, pos-
sibly bridging innate and adaptive immune responses [28].
A crucial issue for an effective immunotherapy of glioma is the definition of the target. Gli-
oma cells with stem cell-like properties are supposed to be essential for tumor initiation and
relapse. These glioma-initiating cells (GIC) are defined by their stem cell-like properties of self-
renewal, multipotency and tumorigenicity in immunodeficient mice, forming tumors resem-
bling the initial human tumors [29, 30]. We recently identified the atypical human leukocyte
antigen (HLA-)-E as an immune-compromising factor in GIC [13]. The interaction of HLA-E
with its receptor, the dimer CD94/NKG2A, leads to inhibition of the lytic activity of natural
killer (NK) cells towards GIC. Moreover, a disintegrin and metalloproteinase (ADAM) 10 and
17 cleave the UL16 binding protein (ULBP) 2 from the cell surface of GIC. This hampers NK
cell activity against GIC since ULBP2 is a ligand of NKG2D. The other NKG2D ligands that
may be expressed on GIC are MHC class I chain-related antigen (MIC)A and -B and UL16
binding protein (ULPB)1-6 [8, 11]. Furthermore, nectin-2 and poliovirus receptor (PVR),
ligands of DNAM–1, are supposed to be important immune-stimulating proteins present on
GIC [11].
Here we define the net effect of IFN-β treatment on the innate immunogenicity of GIC.
Materials and Methods
2.1 Materials and cell lines
The GIC lines GS-2, GS-5, GS-7, GS-8 and GS-9 have been previously characterized for stem
cell properties [31]. LNT–229 glioma were kindly provided by N. de Tribolet (Lausanne, Swit-
zerland) [32] and cultured as described [27]. All GSC lines were cultured in 75 cm2 culture
flasks and maintained in neurobasal medium with B–27 supplement (20 μl/ml) and glutamax
(10 μl/ml) from (all Invitrogen) fibroblast growth factor (FGF)-2, epidermal growth factor
(EGF) (20 ng/ml each; Peprotech, Rocky Hill, PA) and heparin (32 IE/ml; Ratiopharm, Ulm,
Germany). Stem cell factors were supplemented twice a week, complete medium changed once
IFN-βModulates Immune Response against Glioblastoma Initiating Cells
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a week. Cells were passaged when spheres reached an estimated diameter of 500 μm or an esti-
mated density of 5 x 104 cells/cm2. Spheres were dissociated mechanically and enzymatically.
Briefly, we spun down the cells and resuspended the pellet in 1 ml accutase (PAA, Wien, Aus-
tria). After mechanical dissection by pipetting up and down, we incubated the cells at 37°C for
5 minutes. From previous work we know that accutase does not alter the expression level of
NKG2DL on the cell surface of glioma cells [10, 33]. The NK cell line NKL was a gift fromM.
Robertson (Indianapolis, IN) [34] and cells were cultured in RPMI 1640 medium (PAA) con-
taining 15% fetal calf serum (FCS), 2 mM L-glutamine (Gibco Life Technologies, Paisley, UK),
penicillin (100 IU/ml)/streptomycin (100 mg/ml) (Gibco), 1 mM sodium pyruvate and 100 U/
ml interleukin 2 (Peprotech).
IFN-β1b was purchased from AbD Serotec (Dusseldorf, Germany) and reconstituted to a
concentration of 106 IU/ml with distilled H2O. Cell surface expression of immuneregulatory
proteins was assessed with the following monoclonal antibodies (mAbs): HLA-E (clone 3D12;
unconjugated (dilution 1:200) and APC-conjugated (dilution 1:50) mouse IgG1; eBioscience,
Vienna, Austria [13]), MHC-I (clone W6/32; mouse IgG2a, Biologend, Uithoorn, Netherlands,
dilution 1:1000 [13]), PVR and nectin-2 (clones SKII.4, dilution 1:50 and TX31; mouse IgG1,
dilution 1:100 both Biolegend. Optimal conditions were determined by dilution row experi-
ments). Antibodies for MICA, MICB and ULBP1-3 were provided by A. Steinle (Frankfurt,
Germany) [8] and diluted at 1:100 [35]. For NK cell staining, the following antibodies were
used, and optimal conditions were determined by dilution row experiments: CD94 (Clone
REA113, APC-conjugated mouse IgG1, Miltenyi Biotech, Bergisch-Gladbach, Germany, dilu-
tion 1:500), NKG2A (clone REA110, PE-conjugated mouse IgG1, Miltenyi Biotech, dilution
1:200), NKG2C (clone 134591, Alexa Fluor
1
488 conjugated mouse IgG1, R&D Systems, Min-
neanapolis, MA, dilution 1:100), NKG2D (clone 1D11, PE-conjugated mouse IgG1, Biolegend,
dilution 1:1000) and DNAM–1 (ab89394, unconjugated mouse IgG1, Abcam, Cambridge, UK,
dilution 1:1000). Unconjugated IgG1 (clone MOPC 21; Sigma-Aldrich, Buchs, Switzerland)
and IgG2a (clone MOPC–173; Biolegend) or conjugated isotype-matched mAbs were used as
controls (clone MOPC 21; PE-conjugated mouse IgG1, Sigma-Aldrich; Clone: P3.6.2.8.1, APC-
conjugated IgG1, eBioscience; clone MOPC 21; Alexa Fluor
1
488 conjugated IgG1, Biolegend).
The PE-conjugated goat anti-mouse IgG (Dako, Freiburg, Germany) was used as secondary
antibody where appropriate in a dilution of 1:20.
2.2 Flow cytometry
GIC growing as spheres were mechanically dissociated by pipetting and dissolved in Accutase
(PAA, Vienna, Austria) to get a single cell suspension. Adherent cells were detached using
Accutase. The cells were preincubated in PBS with 2% fetal calf serum (FCS) and stained with
specific mAb or matched mouse Ig isotype for 30 min on ice. For unconjugated mAB, staining
was followed by incubation with a PE-conjugated secondary antibody for 30 min respectively.
The cells were washed with PBS containing 2% FCS. Flow cytometry was performed with a
CyAn ADP Analyzer (Beckman Coulter, Nyon, Switzerland). Specific fluorescence index (SFI)
was calculated by dividing median fluorescence obtained with the specific antibody by median
fluorescence obtained with the control antibody.
2.3 Real-Time PCR
RNA was prepared from the cell lines using NucleoSpin RNA II Kit (Macherey-Nagel, Düren,
Germany). Subsequently, cDNA was generated using SuperScript II Reverse Transcriptase
(Invitrogen AG, Basel, Switzerland). RNA and DNA concentrations were determined with the
NanoDrop spectrometer (Thermo Scientific, Waltham, MA). cDNA amplification was
IFN-βModulates Immune Response against Glioblastoma Initiating Cells
PLOS ONE | DOI:10.1371/journal.pone.0139603 October 6, 2015 3 / 16
monitored using SYBRGreen chemistry on the ABI PRISM7000 Sequence Detection System
(Applied Bio-Systems, Weiterstadt, Germany) with the following specific primers (forward/
reverse): GAPDH: 5’-CTCTCTGCTCCTCCTGTTCGAC–3’ (450–469), 5’-TGAGCGAT
GTGGCTCGGCT–3’ (636–619); HLA-E: 5’-GGGACACCGCACAGATTTT–3’ (266–284),
5’CTCA-GAGGCATCATTTGACTTTT (519–497)[14]. Data analysis was done using the ddCT
method for relative quantification. Briefly, threshold cycles (CT) for GAPDH RNA (reference)
and HLA-E (sample) were determined in duplicate. The expression levels were determined fol-
lowing the formula: rI = 2-[CTHLA-E—CT
GAPDH] and standardized to normal brain cDNA (Ams-
bio, Abingdon, UK).
2.4 RNA interference
To silence gene expression, glioma cells were transiently transfected with siRNA molecules tar-
geting specifically HLA-E [14]: (535–553): 5’-GCCUACCUGGAAGACACAU(dTdT)-3’ and
5’-AUGUGUCUUCCA-GGUAGGC(dTdT)-3’, for nectin-2 gene silencing ON-TARGETplus
nectin-2 siRNA (Dharmacon, Lafayette, CO) was applied. ON-TARGETplus Non-Targeting
Pool siRNA (Dharmacon) was used as a control in all gene silencing experiments. Glioma cells
were transfected with 2 nmol siRNA through electroporation with one pulse (1500 mV, 10
ms), using a Neon
1
Transfection system (Invitrogen). The result of gene silencing was verified
by flow cytometry at 24 h after transfection.
2.5 Immune cell cytotoxicity assay
We used a flow cytometry-based cytotoxicity assay which employs the membrane dye PKH–26
and the viability dye ToPro3 [36]. The target cells were stained with PKH–26 membrane dye.
This enables the discrimination of the target cells from the effector cells in the subsequent lysis
assay. Briefly, the target cells were incubated with PKH–26 dissolved in Diluent C (1:250; all
from Sigma-Aldrich) for 3 min. The staining was stopped by washing with RPMI 1640 medium
containing 10% FCS. Then the effector and target cells were co-incubated at varying effector to
target (E:T) ratios for 3 h. Immediately prior to flow cytometry, the viability dye ToPro3 (Invi-
trogen) was added. The percentage of target cell lysis was determined by flow cytometry using
the CyAn ADP Analyzer (Beckman Coulter). Specific lysis was assessed by subtraction of back-
ground lysis.
2.6 Microarray-based gene expression profiling
The technical details have been described elsewhere [27]. Array records are deposited under
GEO accession number GSE53213.
Additional functional GeneOntology (GO) classification of differentially expressed genes
(fold change>2x) was performed using GeneSpring GX (version 12.5; Agilent Technologies).
The corrected enrichment p-value cutoff was set to 0.1. Hierarchical clustering of differentially
expressed transcripts within selected GO terms was done employing Euclidian similarity mea-
sures and Ward´s linkage.
2.7 STRING inquiry
For analysis of functional gene interactions and visualization, data were entered into the Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING) Version 9.1 at http://string-db.
org [37].
IFN-βModulates Immune Response against Glioblastoma Initiating Cells
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2.8 Statistical analysis
The experiments were performed 2 to 3 times as indicated. Statistical significance was calcu-
lated by student`s two-tailed t-test ( p<0.05;  p<0.01). Adobe illustrator
1
CS 6 (version
16.0, Adobe Systems) was used for design of graphics.
Results
3.1 Expression profiling reveals regulation of immune regulatory genes
in GIC upon stimulation with IFN-β
Based on our previous microarray gene expression profiling experiments [27] we analyzed the
changes in the RNA expression pattern of immune regulatory genes upon treatment with IFN-
β in LNT–229 cells and the GIC lines GS-2 and GS-9. Genes involved in the immune response
in general were selected according to the Biological Process Ontology Guidelines (GO:0006955,
http://www.geneontology.org) [38] (Fig 1 and S3 Fig). Moreover, we assessed for genes
involved in the regulation of the innate immune response (GO:0045088) (Fig 1 and S3 Fig).
Furthermore, data were analyzed and visualized employing Search Tool for the Retrieval of
Interacting Genes/ Proteins STRING (S1A–S1C Fig).
The transcripts encoding typical (HLA-A, -B, -C) and atypical MHC proteins (HLA-E, -F
and -G), as well as proteins of the immuno-proteasome (TAP1, PSMB8 and PSMB9) were
increased upon stimulation with IFN-β. Moreover, genes encoding chemokines, toll-like recep-
tors or death receptor ligands were up-regulated (Fig 1, S3 Fig and summarized in S1 Table).
3.2 Alteration of NK cell inhibiting ligand-receptor systems in GIC upon
treatment with IFN-β
We have previously defined a prominent NK cell suppressive effect of HLA-E expression by
GIC [13]. Here we confirmed theHLA-E gene expression in LNT–229 as well as GS-2, GS-5,
GS7, GS8 and GS-9.HLA-EmRNA was up-regulated significantly in LNT–229, GS-5, GS-7
and GS-9 cells (Fig 2A) following stimulation with IFN-β. Accordingly, the cell surface levels of
HLA-E were significantly increased in LNT–229, GS-5, GS-7 and GS-9 cells following stimula-
tion with IFN-β as assessed by flow cytometry (Fig 2B). In GS-2 and GS-8, HLA-E regulation
at the mRNA and protein levels was statistically not significant (Fig 2A and 2B). The regulation
of HLA-E by IFN-β was concentration- and time-dependent with peak HLA-E levels after 24 h
using a concentration of 300 U/ml IFN-β in GS-5 (Fig 2C). In contrast, the expression of the
HLA-E receptors NKG2A and NKG2C as well as their common dimerization partner CD94 on
the NK cell line NKL remained unaltered in response to IFN-β at the same conditions (Fig
2D). The NK cell inhibiting classical HLA-molecule MHC-I was up-regulated only in GS-9,
but remained unaltered in LNT–229, GS-2, GS-5, GS-7 and GS-8 cells upon treatment with
IFN-β (Fig 2E).
3.3 Alteration of the expression of activating ligand-receptor systems in
GIC and NK cells upon treatment with IFN-β
NK cell function is regulated via a balance of inhibiting and activating signals. Thus, we next
assessed the effect of IFN-β on the expression of activating NK cell ligands MICA, MICB,
ULBP1-3 and of nectin-2 and PVR on the cell surface of GIC which might counteract the
immune inhibiting effect of HLA-E up-regulation. The levels of the corresponding receptors
NKG2D and DNAM–1 were assessed on NKL cells. We found a down-regulation of ULBP2 in
GS-2 and GS-9 cells upon treatment with IFN-β, whereas MICA, MICB, ULBP1 and ULBP3
remained unaltered (Fig 3A). The likewise immune stimulating DNAM–1 ligands nectin-2 and
IFN-βModulates Immune Response against Glioblastoma Initiating Cells
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Fig 1. Hierarchical clustering of differentially expressed transcripts.GS-9 cells were treated with IFN-β (300 U/ml, 24h) and the changes in the
transcriptome were assessed using Affymetrix chip-based expression profiling. Immune regulatory genes were identified by functional GeneOntology
analysis of differentially expressed transcripts (fold change (FC)>2x GO:0006955 Immune response (A) and GO:0045087 regulation of innate immune
response (B)). Data is shown as heat map, the color code represents the normalized log expression values.
doi:10.1371/journal.pone.0139603.g001
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Fig 2. IFN-βmodulates the expression of NK cell inhibiting ligand-receptor systems in GIC. A, B.
HLA-EmRNA and cell surface protein levels in LNT–229 and GIC were analyzed following treatment with
IFN-β (300 U/ml, 24 h) by RT-PCR and flow cytometry. C. GS-5 cells were treated with increasing
concentrations of IFN-β or for various time periods (300 U/ml) as indicated. HLA-E surface levels were
assessed by flow cytometry. (D). The cell surface levels of NKG2A and NKG2C and their dimerization partner
IFN-βModulates Immune Response against Glioblastoma Initiating Cells
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PVR were detected on the cell surface of GS-2, GS-5, GS-7, GS-8 and GS-9 by flow cytometry.
Treatment with IFN-β led to an up-regulation of nectin-2 in GS-5, GS-7 and GS-9, but not in
GS-2 and GS-8 while PVR remained unaltered in all cell lines tested (Fig 3B). While the expres-
sion of the activating immune cell receptor NKG2D was significantly up-regulated, DNAM–1
levels on NKL cells did not show any changes following stimulation with IFN-β (Fig 3C). The
modulation of the expression of selected immune regulatory genes and proteins following IFN-
β treatment is summarized in S2 Table.
3.4 The immunogenicity of GIC is modulated upon stimulation with IFN-β
Having assessed the regulation of anti- and pro-immunogenic proteins, we next assessed the
net effects of IFN-β treatment on the innate immunogenicity of GS-2, GS-5, GS-7, GS-8 and
GS-9 cells. While the susceptibility towards NK cell-mediated lysis of GS-2 and GS-8 cells
remained largely unaltered, the cytotoxicity towards GS-5, GS-7 and GS-9 cells was enhanced
upon stimulation with IFN-β as assessed by a flow cytometry-based cytotoxicity assay (Fig 4A–
4E). Moreover, we investigated the role of enhanced HLA-E cell surface levels on NK cell-
mediated immune recognition in these two GIC lines exhibiting altered immunogenicity upon
stimulation with IFN-β. HLA-E expression was silenced using RNA interference following
incubation with IFN-β. The silencing of HLA-E gene expression led to a reduction of more
than 70% of HLA-E cell surface levels, as ascertained by flow cytometry (Fig 4F). As expected,
NKL-mediated lysis was enhanced in GS-5, GS-7 and GS-9 following silencing of HLA-E
expression. The increased lysis following treatment with IFN-β was further enhanced by
HLA-E-gene silencing indicating that the IFN-β-induced up-regulation of HLA-E counteracts
a net immune enhancing effect of IFN-β (Fig 4B, 4C and 4E). Pretreatment of NKL cells with
IFN-β did not influence their cytotoxic activity towards GS cells (S2A and S2B Fig). Therefore,
effects of IFN-β on NK cell receptors seem to be negligible in this context.
We next assessed the role of the up-regulation of nectin-2 for the net immune regulating
effect of IFN-β in GS-9 cells. nectin-2 expression was silenced using sequence-specific RNA
interference in GS-2, GS-5, GS-7, GS-8 and GS-9 cells. The effect of gene silencing on nectin-2
cell surface expression was assessed by flow cytometry, followed by functional lysis assays with
NKL effector cells. nectin-2 levels were reduced by 70–90% in IFN-β pretreated cells. In GS-5
and GS-7 cells, the immune activating effect of IFN-β was abolished by nectin-2 gene silencing,
indicating that enhanced immunogenicity is primarily mediated by nectin-2 in these cells (Fig
5B and 5C). In GS-9 cells, immune activation was only partially reverted, indicating involve-
ment of additional stimulating ligands (Fig 5E). In GS-2 and GS-8, the silencing of nectin-2 led
to reduced cell lysis, however, regardless of treatment with IFN-β.
Discussion
Immunotherapy is a promising approach to improve the outcome of glioblastoma patients.
However, the choice of the target and the use of appropriate adjuvants are crucial. Potential
future adjuvants like imiquimod or polyinosinic:polycytidylic acid lead, among other mecha-
nisms, to enhanced expression of IFN-β. Recent uncontrolled clinical trials indicate a survival
benefit for glioblastoma patients when adding IFN-β to radio- and chemotherapy [23, 39].
Type I IFN up-regulate the expression of co-stimulatory molecules like B7-1/B7-2 and may
CD94 (D) and of MHC class I (E) were assessed by flow cytometry. RT-PCR data are expressed relative to
normal brain cDNA and represent mean relative expression ± SD from 3 independent experiments. Flow
cytometry data represent mean SFI values ± SD from 2 to 3 independent experiments (SFI = 1 is marked with
a dotted line in B, C, D. (** p<0.01, * p<0.05; student`s two tailed t-test).
doi:10.1371/journal.pone.0139603.g002
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Fig 3. IFN-βmodulates the expression of NK cell activating ligand-receptor systems in GIC. The levels of MICA, MICB, ULBP1, ULBP2 and ULBP3 (A)
and of nectin-2 and PVR (B) were assessed by flow cytometry following treatment with IFN-β (300 U/ml, 24 h). C. The levels of NKG2D and DNAM–1 on NKL
cells were assessed following treatment with IFN-β (300 U/ml, 24 h) by flow cytometry (note an almost complete overlay of the flow cytometry curves of
treated and untreated cells). Flow cytometry data represent mean SFI values ± SD from 3 independent experiments (SFI = 1 is marked with a dotted line) (**
p<0.01, * p<0.05; student`s two tailed t-test).
doi:10.1371/journal.pone.0139603.g003
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Fig 4. NKL cell-mediated cytotoxicity assays determine the net effect of IFN-β treatment on GIC. A-E. GS-2, GS-5, GS-7, GS-8 or GS-9 cells were
used as targets in cytotoxicity assays and treated with IFN-β (300 U/ml; 24 h) prior to the cytotoxicity assay with NKL cells as effectors (1 out of 2 independent
experiments shown). GS-5 and GS-9 cells were additionally transfected with siRNA targetingHLA-E or non-targeting siRNA. Specific lysis was calculated by
subtraction of background lysis. In F, HLA-E cell surface levels after HLA-E gene silencing were assessed by flow cytometry (one representative experiment
shown).
doi:10.1371/journal.pone.0139603.g004
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Fig 5. Gene silencing of nectin-2 decreases GIC susceptibility to NKL cell-mediated cell death.GS-2,
GS-5, GS-7, GS-8 or GS-9 cells were transfected with siRNA targeting nectin-2 or non-targeting siRNA as a
control and treated with IFN-β (300 U/ml, 24 h) prior to a cytotoxicity assay using NKL as effectors. In A-E, the
results from the cytotoxicity assay are shown (1 out of 2 to 3 independent experiments shown). The
cytotoxicity assays were run at several effector to target (E:T) ratios in duplicates. In F-J, the respective
nectin-2 cell surface levels following nectin-2 gene silencing were assessed by flow cytometry. Specific lysis
was calculated by subtraction of background lysis.
doi:10.1371/journal.pone.0139603.g005
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therefore enforce the adaptive immune response [40, 41]. However, they might also boost
innate immune responses. In hepatitis C patients, treatment with IFN-α enhanced killing of
infected cells in a DNAM–1 and NKG2D dependent manner [42]. Notably, IFN-β has been
used as an adjuvant in several mouse immunotherapy models. An adenoviral vector encoding
for IFN-β led to a CD8+ T cell dependent reduction of mesothelioma growth [43]. Further-
more, IFN-β enhanced tumor immunity in a vaccine model for leukemia through induction of
WT1-specific cytotoxic T cells and enhancement of NK cell activity [44]. In glioma models,
IFN-β promoted anti-glioma cytotoxic T cell as well as NK cell activity [45] and glioma cells
transfected with IFN-β gene showed enhanced immune recognition via DC and cytotoxic T
cells in vitro and in vivo [46]. These data strengthen the potential usefulness of IFN-β as an
adjuvant for immunotherapy of tumors. The induction of typical and atypical MHC-proteins
is a conserved hallmark of type I and type II interferons [19].
In the present work, we evaluated the changes of the innate immunologic phenotype of glio-
blastoma stem-like cells mediated by IFN-β and define implications for its clinical use as an
adjuvant for immunotherapy targeting GIC. Employing microarray-based expression profiling,
we identified alterations in the expression of several overall immune response and innate
immune response genes, in a panel of well-defined GIC upon treatment with IFN-β (Fig 1 and
S1 Fig). These data revealed an up-regulation of multiple immune regulatory genes including
the atypical MHC proteins HLA-E, -F and -G, genes of the antigen presenting machinery (e.g.
TAP1, PSMB8 and PSMB9), chemokines (e.g. CCL20) and toll like receptors (e.g. TLR3) (Fig
1, S1 Fig, S1 Table). The up-regulation of HLA-E as a potentially immunosuppressive factor is
contrasted by enhanced surface levels of the immune activating molecule nectin-2 while the
level of NKG2D ligands remained largely unaltered (Figs 2 and 3).
Since NK cell function is regulated via a balance of inhibiting and activating signals, we per-
formed NK cell lysis assays to assess the net functional effect of IFN-β on the innate immuno-
genicity of GIC. Despite the up-regulation of HLA-E, we could not find a net inhibitory effect
of IFN-β on NK cell-mediated cytotoxicity towards GIC. NKL cell-mediated cytotoxicity
towards 3 of 5 GIC lines was even increased upon IFN-β treatment, while it remained
unchanged in two cell lines (GS-2 and GS-8) (Fig 4A). A net immune stimulatory effect of
IFN-β was further enhanced upon gene silencing of HLA-E using RNA interference (Fig 4B
and 4C). This indicates that other immune-modulating mechanisms conferred by IFN-βmight
override the HLA-E mediated immune inhibition. We already observed a heterogeneous mod-
ulation of innate immunity towards GIC by IFN-γ. Despite a significant up-regulation of
HLA-E and MHC-I, innate immunogenicity was reduced in only one (GS-5) of the two cell
lines (GS-5 and GS-7) investigated [13]. However, the comparability between type I and II IFN
is limited and should be considered with caution. In the GIC cell lines investigated here, the
concurrent up-regulation of immune stimulatory proteins like nectin-2 counteracted the detri-
mental effect of an up-regulation of HLA-E. In GS-5 and GS-7, we provide direct evidence for
the importance of nectin-2 for the immune stimulating effect of IFN-β. Both cell lines show
enhanced immunogenicity following treatment with IFN-β and this effect was reversed upon
nectin-2 gene silencing (Fig 5B and 5C). Treatment of GS-9 cells with IFN-β led to a similar
up-regulation of nectin-2 on the cell surface compared to GS-5 and GS-7. In contrast, nectin-2
gene silencing did not reverse the immune stimulating effects from IFN-β in GS-9 to the same
degree like in GS-5 and GS-7. The in general sufficient however indeed incomplete silencing of
nectin-2 expression levels might play a role, but the involvement of other receptor-ligand sys-
tems in this particular GS line might better explain these differences. Regarding the NKG2D
system, we did not find alterations of the expression levels of either the ligands or the receptor,
NKG2D, upon treatment with IFN-β in these GS lines (Fig 3A and 3C). This is also true for
the other well-known DNAM–1 ligand PVR and the receptor itself. The natural cytotoxicity
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receptors NKp30, NKp44 and NKp46 could play a role in GS-9 cells, but the respective ligands
are still insufficiently characterized.
Compared to GS-5, GS-7 and GS-9, the GIC lines GS-2 and GS-8 showed only marginal
changes in the expression levels of the immune regulatory proteins investigated here upon
treatment with IFN-β, except for a significant down-regulation of ULBP–2 levels in GS-2 (Figs
2 and 3). In GS-2 and GS-8, IFN-β did not alter the expression levels of nectin-2. Accordingly,
these 2 cell lines show no difference in NK cell-mediated lysis upon treatment with IFN-β. Nev-
ertheless, nectin-2 is important for the immunogenicity of these cells in general since the
silencing of nectin-2 lead to reduced cell lysis, again regardless of treatment with IFN-β. These
results strengthen the importance of nectin-2 for the immune stimulating effect of IFN-β
observed in GS-5 and GS-7. The failure of IFN-β to change the immunogenicity of GS-2 cells
towards NKL cells cannot be explained with a general unresponsiveness of these cell lines tak-
ing into account major changes in the expression of several immune regulatory genes upon
treatment with IFN-β and expression of IFN-β receptors (S1 Table and Happold et al. [27]).
Gene expression analysis revealed 2 different subtypes of the GIC lines used here [31]. GS-5,
GS-8 and GS-9 were characterized by the expression of neurodevelopmental genes and a full
stem-like phenotype while GS-2 and GS-7 exhibited an expression signature enriched for extra-
cellular matrix-related genes with a restricted stem-like phenotype. GIC subtypes might there-
fore also differ in immunological phenotypes.
Altogether, IFN-ß shifts the balance between immune-inhibitory and immune-stimulatory
cell surface markers towards increasing immunogenicity in most experimental systems but in a
heterogeneous fashion.
Our data indicate that IFN-β has at least no detrimental effect on the innate immunogenic-
ity of GIC and thus warrants further investigation as an adjuvant for immunotherapy targeting
GIC. Since the overall functions of IFN-β are more complex, future investigations will focus on
IFN-β-mediated modulation of adaptive immune responses towards GIC.
Supporting Information
S1 Fig. STRING analysis of the modulation of immune regulatory genes upon treatment
with IFN-β. A-C. LNT–229, GS-2 or GS-9 cells were treated with IFN-β (300 U/ml, 24 h) and
the changes in the transcriptome were assessed using Affymetrix Gene Chip HG-U133A 2.0
arrays (Affymetrix, Santa Clara, CA) as reported (Happold et al. 2014). Immunoproteins were
identified according to Biological Process Ontology Guidelines and entered into the STRING
tool. For full names see S2 Table.
(EPS)
S2 Fig. Pretreatment of NKL cells with IFN-β does not alter their immunoreactivity. A, B.
NKL, GS-2 (A) or GS-9 (B) cells were treated with IFN-β (300 U/ml, 24 h) prior to use as effec-
tor or target cells, respectively, in a cytotoxicity assay (n = 2). The cytotoxicity assays were run
at several effector to target (E:T) ratios in duplicates. Specific lysis was calculated by subtraction
of background lysis.
(EPS)
S3 Fig. Expression profiling of immune response genes. GS-2 (A, B) and LNT–229 (C, D)
cells were treated with IFN-β (300 U/ml, 24 h) and the changes in the transcriptome were
assessed using Affymetrix chip-based expression profiling. Results are presented as heat map.
(PDF)
S1 Table. Summary of the modulation of the expression of immune regulatory genes from
RNAmicroarray. LNT–229, GS-2 or GS-9 cells were treated with IFN-β (300 U/ml, 24h) and
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the changes in the transcriptome were assessed using Affymetrix chip-based expression profil-
ing. Immune regulatory genes were identified according to Biological Process Ontology Guide-
lines. Results are summarized in a table, showing the official gene symbol, full name, Probe set
ID (= Gene accession number) and the grade of up-regulation compared to untreated controls.
(PDF)
S2 Table. Summary of the modulation of the expression of selected immune regulatory pro-
teins in GIC and NKL cells by IFN-β. The modulation of immune regulatory genes or surface
proteins upon treatment of GSC and NKL with IFN-β is visualized by arrows, that indicate up-
("), down- (#) or unregulated (!) expression. Only marginal, but formally significant alter-
ations of expression or surface levels were marked with brackets.
(EPS)
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